BIND Therapeutics
BIND Therapeutics: A new way of targeting disease
Investor Relations
Stock price graph

We are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.

View all »   RSSRecent Releases

Apr 7, 2014
BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes of Lead Cancer Drug Candidate, BIND-014, at AACR 2014 Annual Meeting

Mar 25, 2014
BIND Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

View all »Events & Presentations

May 1, 2014
Drug Delivery and Formulations – America's Summit 2014


NASDAQ: BIND
Price:
9.18
Change:
+ 0.18
Day High:
9.30
Day Low:
8.41
Volume:
201,200
4:00 PM ET on Apr 15, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Media Inquiries
Direct media inquiries to:
Gina Nugent
The Yates Network
gina@theyatesnetwork.com

Investor Inquiries
Direct investor inquiries to:
Paul Cox
Stern Investor Relations
212-362-1200
BIND@sternir.com